Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Total Current Liabilities: 2023-2025

Historic Total Current Liabilities for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $61.4 million.

  • Monte Rosa Therapeutics' Total Current Liabilities rose 47.55% to $61.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.4 million, marking a year-over-year increase of 47.55%. This contributed to the annual value of $156.9 million for FY2024, which is 236.85% up from last year.
  • Per Monte Rosa Therapeutics' latest filing, its Total Current Liabilities stood at $61.4 million for Q3 2025, which was up 46.81% from $41.9 million recorded in Q2 2025.
  • Over the past 5 years, Monte Rosa Therapeutics' Total Current Liabilities peaked at $156.9 million during Q4 2024, and registered a low of $19.1 million during Q2 2023.
  • Over the past 3 years, Monte Rosa Therapeutics' median Total Current Liabilities value was $41.9 million (recorded in 2025), while the average stood at $50.3 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first spiked by 236.85% in 2024, then decreased by 1.17% in 2025.
  • Over the past 3 years, Monte Rosa Therapeutics' Total Current Liabilities (Quarterly) stood at $46.6 million in 2023, then skyrocketed by 236.85% to $156.9 million in 2024, then surged by 47.55% to $61.4 million in 2025.
  • Its Total Current Liabilities stands at $61.4 million for Q3 2025, versus $41.9 million for Q2 2025 and $59.2 million for Q1 2025.